PTC Therapeutics (NASDAQ: PTCT) insider files Form 144 to sell shares
Rhea-AI Filing Summary
PTC Therapeutics insider Matthew Klein has filed a Form 144 indicating an intent to sell 3,016 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ market. The shares, with an aggregate market value of $233,691.14, were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation.
Over the prior three months, Klein reported additional sales of the issuer’s common stock, including 3,428 shares on 12/02/2025 for gross proceeds of $271,062.93, 8,089 shares on 12/30/2025 for $619,921.55, and 5,149 shares on 01/06/2026 for $396,203.19. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about PTC Therapeutics.
Positive
- None.
Negative
- None.
FAQ
What does the Form 144 filing for PTC Therapeutics (PTCT) disclose?
The filing shows that Matthew Klein intends to sell 3,016 shares of PTC Therapeutics common stock, with an aggregate market value of $233,691.14, through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ.
How were the 3,016 PTC Therapeutics (PTCT) shares being sold acquired?
The 3,016 common shares were acquired on 01/05/2026 via restricted stock vesting from the issuer, with the nature of payment listed as compensation.
What recent PTC Therapeutics (PTCT) stock sales has Matthew Klein reported?
Over the past three months, Matthew Klein reported sales of PTC Therapeutics common stock of 3,428 shares on 12/02/2025 for $271,062.93, 8,089 shares on 12/30/2025 for $619,921.55, and 5,149 shares on 01/06/2026 for $396,203.19.
Which broker and exchange are involved in the planned PTCT share sale?
The planned sale of 3,016 common shares is to be executed through Fidelity Brokerage Services LLC, with trading on the NASDAQ exchange.
What representation does the seller make in the PTC Therapeutics Form 144?
By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Does the PTC Therapeutics (PTCT) Form 144 mention Rule 10b5-1 trading plans?
The text notes that if the person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1, signing the form and indicating the plan adoption or instruction date serves as a representation as of that date.